Login / Signup

Severely complicated ear infection in a patient treated with ixekizumab: a case report.

Léonore MaertensNaomi PolletMarta ClarysseLore VanderbekeNicolas VerhaertChristian DesloovereElke Loos
Published in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024)
We report a case of a severe ear infection in a 35-year-old man treated with ixekizumab for psoriasis. Ixekizumab is a humanized monoclonal antibody that selectively prevents the interaction between interleukin 17 A and its receptor. Biologicals like ixekizumab are used to achieve symptom relief in autoimmune diseases including psoriasis. Unlike the mild upper respiratory tract infections usually described as side-effects of this treatment, we report a case of a patient who presented with a severe otitis media, complicated with a facial paresis and nasopharyngeal abscess. To the best of our knowledge, this is the first case presenting a severe, complicated ear infection as a possible side effect of ixekizumab. We conclude that when using ixekizumab, vigilance for upper airway infections is needed and if necessary, interruption of therapy should be considered. However, further research is needed to confirm this hypothesis.
Keyphrases
  • monoclonal antibody
  • respiratory tract
  • case report
  • early onset
  • healthcare
  • stem cells
  • mouse model
  • mesenchymal stem cells
  • replacement therapy
  • soft tissue
  • rare case